Diabetes, cardiovascular drug targets
May. 24, 2022—Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Pushing (anti-overdose) drugs
May. 23, 2022—An automated alert to encourage clinicians to coprescribe naloxone for patients at risk of opioid overdose increased naloxone prescriptions per opioid prescription 16-fold.
Genetics and blood pressure
May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.
A clue to an adverse drug event in children
May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.
Autism and sleep problems
May. 10, 2022—Vanderbilt researchers developed a framework for using de-identified medical records to characterize sleep in people on the autism spectrum — a framework that should also be useful for studying other neurodevelopmental disorders.
Gene variants and transplant drug dose
May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.
COVID-associated bleeding risk
May. 5, 2022—While case reports have noted acquired hemophilia after COVID-19 infection or vaccination, a new study finds no increased risk.
Gene network linked to Type 2 diabetes
May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.
Calculating risk for uterine fibroids
Apr. 26, 2022—Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
When science spills onto social media
Apr. 21, 2022—Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.
Youthful healing for burn wounds
Apr. 21, 2022—Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered.